

REMARKS

Claims 1-16 were pending in the present application. Claims 1-3, 5, 9, 10, and 13-16 have been amended. No new subject matter has been introduced. Claims 1-16 remain pending in this application.

Claims 1, 2, 3, 5, and 9 have been amended to correct typographical errors and grammatical omissions. Claim 10, which depends from product claim 8, has been amended to clarify that the claim is directed to a coated stent, rather than a use. Claims 13-16 have been amended to present claims directed to a method of selecting a stent rather than a use. All amendments are supported by the original specification and claims, as filed.

Restriction

The Examiner has required restriction between:

Group I, claims 1-16, drawn to a stent structure with a compound with at least three vicinally oriented phosphorous-containing radicals (moieties).

Group II, claims 10 and 13-16, drawn to a method of using a stent structure coated with a compound with at least three vicinally oriented phosphorous radicals (moieties).

In response to the restriction requirement, Applicant elects Group I, claims 1-16. In response to the Examiner's remarks regarding claims 10 being interpreted as "being drawn to both a process and a product," Applicant notes that claim 10 has been amended to clarify that the claim is directed to only a product.

Election of Species

The Examiner has required election of a particular species of compound with at least three vicinally oriented phosphorous-containing radical (moieties).

In response to the requirement, Applicant elects "D-3,4,5-tri-O-(phenylcarbamoyl) myo-inositol-1,2,6-trisphosphate." This compound was presented in Example 2 of the specification, as original filed.


Applicant expressly reserves the right under 35 U.S.C. § 121 to file a divisional application directed to the nonelected subject matter.

CONCLUSION

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No.: 03-1952** referencing **514862007400**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 16, 2008

Respectfully submitted,

By 

Michael R. Ward

Registration No.: 38,651

MORRISON & FOERSTER LLP

425 Market Street

San Francisco, California 94105-2482

415.268.6237